Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy.

This study aims to evaluate the impact of a one-week discontinuation of long-acting glucagon-like peptide-1 receptor agonists (GLP-1 RAs) prior to Esophagogastroduodenoscopy on gastric preparation quality and the need for repeat esophagogastroduodenoscopy (EGD), in order to determine whether a one-week drug interruption constitutes an appropriate pre-procedural recommendation.

NCT Number	NCT07736911
Lead Sponsor	Fu Jen Catholic University Hospital
Conditions	GLP-1
Enrollment	140 participants
Start Date	2026-06-01
Primary Completion	2029-06-01 (estimated)
Study Completion	2030-06 (estimated)
Updated on ClinicalTrials.gov	2026-07-30